Protego Biopharma
Latest round
- Series B
Last raised
- Oct 2025
Total raised
- $84M
Investors
- 10
About Protego Biopharma
Protego Biopharma, Inc. specializes in developing innovative small molecule therapeutics aimed at treating protein misfolding diseases, utilizing advanced pharmacological chaperones to restore protein function and improve patient outcomes., based in California, US, focuses on creating therapeutics for protein misfolding diseases. In October 2025, Protego Biopharma, Inc. CEO Richard Labaudiniere leads the company, which has maintained its strategic focus since inception without any pivots or changes in operations. Protego BioPharma is dedicated to developing first-in-class small molecule therapeutics that target protein misfolding diseases. The company's core offerings focus on pharmacological chaperones, which are designed to bind to and stabilize misfolded proteins, restoring their normal structure and function. These therapeutics aim to treat a variety of serious conditions, including myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. The innovative discovery platform employs advanced techniques such as bioinformatics and clinical pathology analysis, ensuring that the products address significant unmet medical needs. Protego BioPharma markets its solutions primarily in North America, Europe, and select regions in Asia, targeting healthcare providers, research institutions, and pharmaceutical partners engaged in precision medicine. Revenue generation for Protego BioPharma occurs through strategic partnerships with research institutions and pharmaceutical companies, leveraging B2B relationships to facilitate the use of their therapeutics in clinical settings. Transactions typically involve collaborative agreements where Protego provides its pharmacological chaperones to partners for development and testing in specific disease contexts. Pricing structures are determined through negotiated contracts, often reflecting the therapeutic's value in addressing high unmet medical needs. Key offerings, such as those inspired by the established pharmacological chaperone tafamidis, represent flagship products that are central to the company’s revenue model. By focusing on innovative solutions that enhance patient outcomes, Protego BioPharma aligns its financial interests with the needs of its partners and the end-users of its products. The firm is actively designing and preparing to launch new therapeutics aimed at protein misfolding diseases. Specific geographic expansions are being targeted in North America, Europe, and select regions in Asia to enhance market reach.
Who invested in Protego Biopharma
10 investors across 2 rounds
See all investors in Protego Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Protego Biopharma
Who invested in Protego Biopharma?
Protego Biopharma has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Protego Biopharma raised?
Protego Biopharma has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Protego Biopharma last raise money?
Protego Biopharma's most recent round on record is a Series B, in Oct 2025.
What does Protego Biopharma do?
Protego Biopharma is a biotechnology company.
Where is Protego Biopharma headquartered?
Protego Biopharma is headquartered in San Diego, US.
Which VCs invest in companies like Protego Biopharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Protego Biopharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Protego Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.